Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer

Giuseppe Saltalamacchia, Mara Frascaroli, Antonio Bernardo, Erica Quaquarini

Research output: Contribution to journalReview articlepeer-review


Prostate cancer (PC) is the most common male cancer in Western Countries. In recent years, the treatment of relapsed or metastatic disease had benefited by the introduction of a variety of new different drugs. In consideration of the relative long survival of PC patients, side effects of these drugs must be considered and monitored. In this review, we analyzed the newly developed therapies for PC treatment, describing the mechanism of action, the metabolism and latest clinical trials that led to the approval of these drugs in clinical practice. We then evaluated the cardiovascular and renal side effects from pivotal phase III and II studies and meta-analyses. Cardiovascular side effects are the most frequent, in particular hypertension, while renal toxicity is rarer and not well described in literature. Therefore, there is a need to better define the effects of these therapies, in order to personalize patient treatment on the basis of their comorbidities and preferences, in addition to their symptoms and disease load.

Original languageEnglish
Article number1750
Issue number7
Publication statusPublished - Jul 1 2020

Fingerprint Dive into the research topics of 'Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer'. Together they form a unique fingerprint.

Cite this